Fundraising Fox
Forcyte Biotechnologies
DefunctYC W21Los Angeles, US · Founded 2017 · Delaware corporation · 5 employees · 9 known investors
Find your way into Forcyte Biotechnologies
Sign up to see every warm intro you have to Forcyte Biotechnologies
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Forcyte Biotechnologies team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Forcyte Biotechnologies develops drug screening tools that measure cell contractility to identify therapeutic candidates for diseases driven by abnormal cellular force generation, such as asthma, fibrosis, and hypertension.
Founders & leadership· Y Combinator alumni (W21)
Forcyte Biotechnologies was founded in 2017 by Ivan Pushkarsky and Dino Di Carlo.
Investors · 9
How we know: Jude Gomila's portfolio page · Y Combinator's founder network · Not right? Tell us
How we know: the Y Combinator directory · funding news · press coverage · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: funding news · Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
How we know: Y Combinator's founder network · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$160K disclosed across 1 round · 2018
▶$160KraisedJan 2019 · 3 investors · Other TechnologyRule 506(b)
- Ivan PushkarskyExecutive Officer
- Offering amount
- $2M
- Amount sold
- $160K
- Minimum investment
- $25K
- First sale
- Dec 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 5
Companies working in the same space as Forcyte Biotechnologies.
Non-dilutive funding · 6 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $394.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2021 | $350K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $288K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $225K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Legal entities · 1
corporate structureIn the news
Frequently asked questions
- What does Forcyte Biotechnologies do?
- Forcyte Biotechnologies develops drug screening tools that measure cell contractility to identify therapeutic candidates for diseases driven by abnormal cellular force generation, such as asthma, fibrosis, and hypertension.
- Who founded Forcyte Biotechnologies?
- Forcyte Biotechnologies was founded by Ivan Pushkarsky, Dino Di Carlo in 2017.
- Who are Forcyte Biotechnologies's investors?
- Forcyte Biotechnologies's investors include BVP Investors, Jude Gomila, Sprint Vc, Y Combinator, Acequia Capital (AceCap), Asymmetry Ventures, FAST — by GETTYLAB, Meron Capital and 1 more.
- How much funding has Forcyte Biotechnologies raised?
- Forcyte Biotechnologies has disclosed $160K raised across 1 round.
- Where is Forcyte Biotechnologies headquartered?
- Forcyte Biotechnologies is headquartered in Los Angeles, US.